1741P Atezolizumab (ATZ) with split-doses of cisplatin plus gemcitabine in patients with locally advanced or metastatic urothelial carcinoma (SOGUG-AUREA): A multicentre, single-arm phase II trial

Autor: G.A. De Velasco Oria, I. García-Carbonero, E. Esteban-Gonzalez, A. Pinto, D. Lorente, A. Gómez de Liaño, E. Martínez Ortega, L. Jimenez Colomo, J. Puente, I. Gonzalez, O. Fernández, G. Anguera

Publikováno v: Annals of Oncology. 33:S1333

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1ee456de7b88c687078c105bc224a579
https://doi.org/10.1016/j.annonc.2022.07.1819

HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies

Autor: D.J. Khalaf, I.M. Aragón, M. Annala, R. Lozano, S. Taavitsainen, D. Lorente, D.L. Finch, N. Romero-Laorden, J. Vergidis, Y. Cendón, C. Oja, M.I. Pacheco, M. Zulfiqar, M.E. Gleave, A.W. Wyatt, D. Olmos, K.N. Chi, E. Castro, E. Almagro, J.Á. Arranz, E.G. Billalabeitia, P. Borrega, J.A. Contreras, M. Domenech, R. Escribano, E. Fernández-Parra, E. Gallardo, I. García-Carbonero, R. García, J. Garde, A. González del Alba, B. González, A. Hernández, S. Hernando, P. Jiménez, N. Laínez, R. Luque, E. Martínez, A. Medina, M.J. Méndez-Vidal, A. Montesa, R. Morales, null Olmos David, J.L. Pérez-Gracia, B. Pérez-Valderrama, Á. Pinto, J. Piulats, J. Puente, R. Querol, A. Rodríguez-Vida, M.I. Sáez, S. Vázquez, E. Vélez, J.C. Villa-Guzmán, R. Villatoro, C. Zambrana

Background A common polymorphism (1245A>C) in the HSD3B1 gene is associated with increased de novo synthesis of androgens and worse outcomes in men treated with androgen-deprivation therapy for metastatic castration-sensitive prostate cancer. The obj

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9314d3782c3e9be3bf57d8cc86f7fa53
https://hdl.handle.net/10668/15803

1874P Impact of infections and antibiotic therapy in a cohort of patients with advanced solid cancers who receive immune checkpoints inhibitors. An observational, retrospective study

Autor: E. Martinez Moreno, J.M. Andrade Santiago, A.M. Ramos Garrido, K. Martinez Barroso, I. García Carbonero, M. Borregon Rivilla, J.D. Cardenas, R. Alvarez Cabellos, L. Fernández Franco, C. Esteban Esteban, J.I. Chacon Lopez-Muniz, I. Ramos Reguera, M.A. Mazariegos Rubi, J. Medina Martínez, A.K. Santos Rodríguez, B. Berzal Hernández

Publikováno v: Annals of Oncology. 31:S1068

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::389e87adbe212d24f11f76070f0f069f
https://doi.org/10.1016/j.annonc.2020.08.1521

Baseline

Autor: A M, García Vicente, B, González García, M, Amo-Salas, I, García Carbonero, J, Cassinello Espinosa, J L, Gómez-Aldaraví Gutierrez, L, Suarez Hinojosa, Á, Soriano Castrejón

Publikováno v: Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 21(3)

To establish the utility of baselineProspective, multicenter and non-randomized study (ChoPET-Rad study). FCH PET/CT and BS were performed before the initiation ofForty patients were evaluated. The median PFS and OS were of 3.0 ± 2.3 and 23.0 ± 4.2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::42006a51774a7ec46f5296eadc844ced
https://pubmed.ncbi.nlm.nih.gov/30006674

Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study

Autor: A. González del Alba, J.L. González Larriba, G. Rubio Romero, B. Pérez-Valderrama, J.L. Puertas Álvarez, D.E. Castellano Gaunas, R. García Domínguez, J. J. Garcia, S. Vazquez Estevez, C. Santander Lobera, J.A. Meana García, C. Molins Palau, R.D. García Marrero, M. López Brea, O. Reig Torras, M. Lázaro Quintela, I. García Carbonero, E.M. Fernandez Parra, L. Basterretxea Badiola, P. Gajate Borau, C. Maximiano Alonso, J.J. Lambea Sorrosal, J.C. Villa Guzman, J.A. Arranz Arija, E. Vélez de Mendizábal, M.J. Juan Fita, C. Suarez Rodriguez, P. Jiménez Gallego, Á. Rodríguez Sánchez, L. León-Mateos, A. Pinto Marin, M.J. Mendez Vidal, P. Borrega García, I. Chirivella Gonzalez

Publikováno v: ANNALS OF ONCOLOGY
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Annals of oncology : official journal of the European Society for Medical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-FISABIO. Repositorio Institucional de Producción Científica

The International Metastatic Renal-Cell Carcinoma Database Consortium prognostic classification for patients treated with first-line tyrosine kinase inhibitors did not include patients treated with pazopanib. A validation for this subset is presented

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca7d041d59dbe1d12852c7ebbc5d820b
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1253